



# Patents

From foundational patents to delivery technology, we have pioneered the development of mRNA medicine since our founding. Along the way, we have accumulated a broad collection of patents, with several hundred additional pending patent applications.

## Intellectual Property

**The following articles are protected by the following United States patents for Moderna Inc.**

**Spikevax™ (mRNA-1273 COVID-19 VACCINE)**

[US 11,485,972](#)

[US 10,898,574](#)

[US 10,703,789](#)

[US 10,702,600](#)

[US 10,577,403](#)

[US 10,442,756](#)

[US 10,266,485](#)

[US 10,064,959](#)

[US 9,868,692](#)

**In addition, Moderna Inc. owns additional patents in the United States and foreign jurisdictions.**

## Investors

[Investors overview](#) 

## Newsroom

[News and media](#)

[Media kit](#)

## Patents

[Patents](#)

## Media Center

All media

Blogs

Videos

Podcasts

## Partnerships

Strategic collaborators

## Careers

Life at Moderna

People behind the science

Awards

Join our team 

## Innovation Incubator

New Venture Labs



[Terms of use](#)

[Privacy statement](#)

[Contact Moderna](#)

[Sitemap](#)

© 2022 Moderna, Inc.